A new publication reports that 91 of colorectal cancers were detected at 90 specificity in a completed prospective trial using Volition's Nu.QTM assays

NAMUR Belgium May 18 2017 PRNewswire VolitionRx Limited NYSE MKT VNRX today announced the publication of a research paper entitled "Circulating nucleosomes as new bloodbased biomarkers for detection of colorectal cancer". The study was published...